• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

溃疡性结肠炎合并丙型肝炎:罕见情况。

Ulcerative colitis coexisting with hepatitis C: A rare occurrence.

机构信息

Department of Gastroenterology, First Hospital of Quanzhou Affiliated to Fujian Medical University, Quanzhou, Fujian, China.

出版信息

Medicine (Baltimore). 2023 Dec 15;102(50):e36629. doi: 10.1097/MD.0000000000036629.

DOI:10.1097/MD.0000000000036629
PMID:38115293
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10727529/
Abstract

INTRODUCTION

We describe a rare case of a 54-year-old male diagnosed with both ulcerative colitis (UC) and hepatitis C virus (HCV), posing clinical challenges.

PATIENT CONCERNS

The patient showed worsened UC symptoms, leading to further evaluations.

DIAGNOSIS

Dual diagnosis of UC and HCV was confirmed through endoscopy and serological tests, ruling out other hepatic causes. Interventions: Treatment involved methylprednisolone for UC and sofosbuvir/velpatasvir for HCV, with attention to drug interactions.

OUTCOMES

Significant improvement was observed in both UC symptoms and HCV viral load post-treatment.

CONCLUSION

This case underscores the need for nuanced treatment in managing concurrent UC and HCV, considering potential drug interactions and disease impacts.

摘要

简介

我们描述了一例罕见的 54 岁男性病例,他同时被诊断患有溃疡性结肠炎(UC)和丙型肝炎病毒(HCV),这给临床治疗带来了挑战。

患者主诉

患者的 UC 症状恶化,需要进一步评估。

诊断

通过内镜检查和血清学检测,确诊为 UC 和 HCV 的双重诊断,排除了其他肝脏病因。

干预措施

针对 UC 采用了甲泼尼龙治疗,针对 HCV 采用了索磷布韦/维帕他韦治疗,并注意药物相互作用。

结果

治疗后,UC 症状和 HCV 病毒载量均显著改善。

结论

该病例强调了在治疗同时患有 UC 和 HCV 的患者时需要细致考虑,包括潜在的药物相互作用和疾病影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6b5/10727529/83fc882dc09c/medi-102-e36629-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6b5/10727529/cd90438d2193/medi-102-e36629-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6b5/10727529/83fc882dc09c/medi-102-e36629-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6b5/10727529/cd90438d2193/medi-102-e36629-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6b5/10727529/83fc882dc09c/medi-102-e36629-g002.jpg

相似文献

1
Ulcerative colitis coexisting with hepatitis C: A rare occurrence.溃疡性结肠炎合并丙型肝炎:罕见情况。
Medicine (Baltimore). 2023 Dec 15;102(50):e36629. doi: 10.1097/MD.0000000000036629.
2
Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report.在一名溃疡性结肠炎患者中,通过减少利巴韦林剂量成功使用索磷布韦治疗丙型肝炎病毒2型慢性感染:病例报告
BMC Gastroenterol. 2016 Jul 11;16(1):66. doi: 10.1186/s12876-016-0480-x.
3
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.索磷布韦和维帕他韦治疗 1、2、4、5、6 型 HCV 感染。
N Engl J Med. 2015 Dec 31;373(27):2599-607. doi: 10.1056/NEJMoa1512610. Epub 2015 Nov 16.
4
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.索磷布韦和维帕他韦治疗 2 型和 3 型丙型肝炎病毒感染。
N Engl J Med. 2015 Dec 31;373(27):2608-17. doi: 10.1056/NEJMoa1512612. Epub 2015 Nov 17.
5
Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial.索磷布韦/维帕他韦治疗亚洲慢性丙型肝炎病毒感染:一项单臂、开放标签、3 期临床试验。
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):127-134. doi: 10.1016/S2468-1253(18)30343-1. Epub 2018 Dec 14.
6
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.索磷布韦和维帕他韦联合利巴韦林或不联合利巴韦林治疗丙型肝炎病毒基因型 3 感染合并肝硬化患者的疗效。
Gastroenterology. 2018 Oct;155(4):1120-1127.e4. doi: 10.1053/j.gastro.2018.06.042. Epub 2018 Jun 27.
7
Prevalence of Hepatitis C Virus Infection and Efficacy of Sofosbuvir-Velpatasvir and Sofosbuvir-Daclatasvir Treatment Regimens in End-stage Renal Disease Patients on Maintenance Hemodialysis.终末期肾病维持性血液透析患者丙型肝炎病毒感染的流行情况及索磷布韦-维帕他韦和索磷布韦-达拉他韦治疗方案的疗效。
Saudi J Kidney Dis Transpl. 2023 Nov 1;34(6):570-575. doi: 10.4103/sjkdt.sjkdt_19_23. Epub 2024 May 9.
8
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.索磷布韦维帕他韦片治疗失代偿期肝硬化的丙型肝炎病毒感染。
N Engl J Med. 2015 Dec 31;373(27):2618-28. doi: 10.1056/NEJMoa1512614. Epub 2015 Nov 16.
9
Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.达卡他韦联合索非布韦和维帕他韦/索非布韦治疗丙型肝炎 2 型和 3 型的真实世界疗效。
J Hepatol. 2019 Jan;70(1):15-23. doi: 10.1016/j.jhep.2018.09.018. Epub 2018 Sep 26.
10
Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency.索磷布韦为基础的直接作用抗病毒治疗在严重肾功能不全患者丙型肝炎病毒感染中的应用。
Infect Dis (Lond). 2015;47(12):924-9. doi: 10.3109/23744235.2015.1078908. Epub 2015 Aug 18.

本文引用的文献

1
Prevalence of hepatitis B virus and hepatitis C virus infection in patients with inflammatory bowel disease: a systematic review and meta-analysis.炎症性肠病患者中乙型肝炎病毒和丙型肝炎病毒感染的患病率:一项系统评价和荟萃分析。
Intest Res. 2023 Jul;21(3):392-405. doi: 10.5217/ir.2022.00094. Epub 2022 Dec 2.
2
Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment.英夫利昔单抗诱导的肝损伤:临床表型、自身免疫和皮质类固醇治疗的作用。
J Hepatol. 2022 Jan;76(1):86-92. doi: 10.1016/j.jhep.2021.08.024. Epub 2021 Sep 3.
3
Epidemiology and Pathogenesis of Ulcerative Colitis.
溃疡性结肠炎的流行病学和发病机制。
Gastroenterol Clin North Am. 2020 Dec;49(4):643-654. doi: 10.1016/j.gtc.2020.07.005. Epub 2020 Sep 25.
4
EASL recommendations on treatment of hepatitis C: Final update of the series.EASL 丙型肝炎治疗建议:系列的最终更新。
J Hepatol. 2020 Nov;73(5):1170-1218. doi: 10.1016/j.jhep.2020.08.018. Epub 2020 Sep 15.
5
A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches.基于计算机模拟方法比较研究 HCV NS3/4A 蛋白酶抑制剂对不同 HCV 基因型的效率。
Life Sci. 2019 Jan 15;217:176-184. doi: 10.1016/j.lfs.2018.12.004. Epub 2018 Dec 4.
6
Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice.东欧、亚洲和拉丁美洲的结核病与病毒性肝炎感染:肿瘤坏死因子-α抑制剂在临床实践中的影响
Biologics. 2018 Jan 12;12:1-9. doi: 10.2147/BTT.S148606. eCollection 2018.
7
Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases.丙型肝炎病毒感染合并炎症性肠病患者直接抗病毒药物和生物制剂给药的时机策略
Front Pharmacol. 2017 Nov 21;8:867. doi: 10.3389/fphar.2017.00867. eCollection 2017.
8
Recent Advancement of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy.直接作用抗病毒药物(DAAs)在丙型肝炎治疗中的最新进展
Mini Rev Med Chem. 2018;18(7):584-596. doi: 10.2174/1389557517666170913111930.
9
Literature review in cases with exacerbation of ulcerative colitis induced by treatment with interferon and/or ribavirin.文献回顾:干扰素和/或利巴韦林治疗引起溃疡性结肠炎恶化的病例。
J Gastroenterol Hepatol. 2011 Dec;26(12):1709-16. doi: 10.1111/j.1440-1746.2011.06890.x.
10
Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy.炎症性肠病患者接受免疫抑制治疗时与乙型肝炎和丙型肝炎相关的肝功能障碍。
Gut. 2010 Oct;59(10):1340-6. doi: 10.1136/gut.2010.208413. Epub 2010 Jun 24.